STOCKS TELEGRAPH

Author: ST Staff

  • Why Has CLSD Stock Skyrocketed In Premarket Trading?

    Why Has CLSD Stock Skyrocketed In Premarket Trading?

    Shares of Clearside Biomedical Inc. (CLSD) were up 35.10% in premarket trading at $4.08. By the close of last session, CLSD’s stock was trading at $3.02, +0.33%, or $0.01. The share price of Clearside stock has increased 52.53% over the previous twelve months, and has fallen by -4.43% over the past one week. As a result of the positive safety results of an ongoing clinical study, CLSD stock has been skyrocketing before the market opens.

    For what purpose was that study conducted?

    Clearside Clearside is a biopharmaceutical company that develops and manufactures treatments that restore and preserve vision in people with serious diseases of the back of the eye. The CLSD SCS Microinjector is designed to deliver fluid directly into the suprachoroidal space (SCS) and grants unparalleled access to the macula, retina, and choroid areas, where sight-threatening diseases often develop.

    Located inside an office, CLSD’s SCS injection platform provides a non-surgical, inherently flexible, non-invasive process for delivering medication to the site of disease and is capable of working with both established and new forms of medications.

    Clearside today reported today positive safety results from Cohort 1 of this ongoing Phase 1 / 2a clinical trial of its CLS-AX shot via its SCS Micro Injector device into six patients with neovascular age-related macular degeneration (wet AMD).

    • The primary endpoints were achieved in Cohort 1, when CLS-AX was well tolerated at the lowest planned dose of 0.03 mg.
    • CLSD’s Cohort 1 did not exhibit any serious adverse events or treatment-related adverse events during the study period.
    • No signs of inflammation, no vasculitis, no intraocular pressure (IOP)-related negative safety signals, no drug dispersion or any other adverse events associated with the medication were observed in any of the patients reviewed by CLSD.

    CLSD’s further plans for the study:

    After reviewing the data OASIS Safety Monitoring Committee at Clearside (CLSD) has moved the study to Cohort 2. CLSD expects to start Cohort 2 of screening patients to receive 0.1 mg of CLS-AX in June 2021 with completion of this four-month study expected by December 2021.

  • Is Apple Inc. (AAPL) stock attractive in 2021?

    Is Apple Inc. (AAPL) stock attractive in 2021?

    We are living in an era where smartphones, tablets, computers, and laptops, etc. have now become the necessities of every single house. Imagine a life without a smartphone and you will find yourself to be non-functional without it. Evolution in information technology has given rise to the invention of many new digital devices and companies like Apple Inc. (AAPL) Stock, Sony Group Corp (SONY), Dell Technologies Inc (DELL), and many others have greatly contributed to this development. Apple alone has introduced many devices till now ranging from personal computers to smartwatches.

    So, it is very natural to think of investing in AAPL stock for a long-term gain prospect as it has shown significant growth over time and has earned a large number of profits over the years. In the last five years, the shares of Apple Inc. (AAPL) skyrocketed almost 419%. Apple Inc. (AAPL) is currently trading with $130.39 per share on June 15, 2021, as of this writing. Let’s take a closer look at Apple stock.

    Apple’s iPhone 12 Series & VR/AR Development:

    The iPhone 12 series which also supports the 5G technology is playing a major role in steadily growing AAPL stock price and estimates by the suppliers show that the 230 million iPhones could be shipped in the year 2021.iPhone 12 series is not alone major contributor in the company’s future growth as Apple’s VR/AR and mixed reality headset will be launch in the upcoming year with a hefty price tag of $3,000 with Apple pair of AR glasses to follow in 2025.

    Apple’s Services Business:

    Besides Apple’s hardware products, the stock is doing smart business in its services segment. In order to expand its audience across the globe, the AAPL stock has launched  Apple News+, Apple TV+, and Apple Fitness+ in the past couple of years which resulted in the $33 billion revenue in the first half of 2021 representing 25% growth over the year.

    Electric Vehicle Development:

    The big tech company is also paying attention to the development of electric vehicles as it is discussing supply deals with certain Chinese battery companies and the first electric vehicle by AAPL stock is expected to be launch between 2024 to 2026 according to analyst’s suggestion, which could prove to be the game-changer for the giant tech stock.

    Financial View of the AAPL stock:

    AAPL stock sales have been increased by 54% in the second quarter of the fiscal year 2021 representing a 66% improvement in the revenue gained from the iPhone over the year. Earnings per share increased by 119% in the recently reported quarter and $24 billion was recorded for operating profit out of which $23 billion was given back to the shareholders through share repurchases and dividends.  The quarterly payout was increased by 7% and the business is strengthened by the addition of $90 billion in the existing share repurchase plan.

    Wrap Up:

    Apple Inc. (AAPL) has captivated investors for decades and earned huge profits for them over time. Its evolutionary iPhone 12 series, VR/AR headsets, and upcoming pair of AR glasses show that the future is bright for Apple Inc. (AAPL). The significant increase in the services business is another positive sign for the giant tech stock. In a nutshell, long-term investment prospects are bright for AAPL stock.

  • How Did The REMSleep (RMSL) Stock Drop 12%?

    The stock of REMSleep Holdings Inc [OTCPINK: RMSL] was down -12.00% to $0.0176 at the previous close. REMSleep stock recorded volume of 4.69M shares compared to its 30-day average volume of 5.68M shares. RMSL stock price ranged from $0.0012 to $0.0472 in the past 52 weeks. Since the RMSL stock has risen in spite of lack of news, recent developments can be useful in gaining insight into the RMSL.

    How did RMSL fare recently?

    REMSleep manufactures medical devices aimed at giving patients with obstructive sleep apnea a better treatment experience forever. RMSL’s primary focus is designing and manufacturing products to treat sleep apnea and other respiratory problems. RMSL’s team has over 30 years of CPAP therapy experience, so they are well-versed in this therapy and the challenges of compliance.

    REMSleep announced this month that it has engaged Empirical Technologies Corp (ETC) to assist it with the 510K process.

    • As a result of slow progress in its 510K submission, RMSL has become frustrated.
    • RMSL’s 510K submission will be streamlined by partnering with ETC, which will ensure the 510K submission gets to the right place.
    • REMSleep plans to work with ETC on all future regulatory matters.
    • The RMSL acknowledged that ETC submissions for 510K approval were approved 20% to 40% faster than industry average.
    • RMSL is confident in ETC’s ability to submit 510K’s since it has a 100% success rate.
    • The utility patent application filed by REMSleep in April 2021 has been approved.

    Why is RMSL focusing so much on filing?

    Remsleep (RMSL) will launch a marketing campaign for its utility patent once the 510k clearance process has been completed. Future products will be released with greater ease and speed as RMSL continues to develop new products.

  • Why The Ampio (AMPE) Stock Is Up 15% In Pre-Hours?

    Shares of Ampio Pharmaceuticals Inc. (AMPE) were last seen at $2.08 in premarket trading, up 15.56%. Ampio stock closed last session at $1.80, gaining 1.12%, or $0.02. AMPE stock traded between $1.77 and $1.83 during the past session.

    Volume of the traded shares was 1.24 million, a lower number than AMPE’s 50-day volume of 1.43 million and below its Year to Date volume of 2.73 million. AMPE stock has surged after receiving approval to expand enrollment in a study.

    Which study received approval?

    Biopharmaceutical company Ampio focuses on developing immunological-based treatments for common inflammatory conditions for which limited treatment options exist. AMPE’s lead drug, Ampion, is protected by a broad patent portfolio that lasts until 2035. AMPE’s that drug will also qualify for 12-year FDA market exclusivity once it is approved as a novel biologic under the biologic price competition and innovation act (BPCIA).

    Today, Ampio announced that regulatory approval had been received for the expansion of enrollment of its AP-019 Phase II study to India.

    • Patients suffering from respiratory distress due to COVID-19 will be treated with inhaled Ampion in the study.
    • The FDA approval of AMPE’s therapy for study in India highlights the need for the treatment to continue.
    • There are currently more than 3,200 deaths per day due to COVID-19 in India, and more than 94,000 new cases are reported daily.
    • The expansion of the study should shorten the enrollment period and benefit a population afflicted with COVID-19 among the highest densities anywhere in the world.
    • Using the results from its AP-014 Phase I trial, Ampion was used in the AP-019 double-blind, placebo-controlled Phase II study.
    • AMPE announced on April 27, 2021, that the earlier Phase I study had met its primary endpoints of safety and tolerability.
    • Additionally, the top-line results in that AMPE study showed that Ampion reduced COVID-19 respiratory distress all-cause mortality by 78% over Standard of Care (SOC).
    • In those treated with SOC, mortality was 24%, compared to only 5% in those treated with Ampion.

    Why AMPE has reallocated?

    Ampio (AMPE) has made the strategic decision to discontinue the AP-019 study efforts in Israel due to the current political unrest in Israel and the surrounding region. As a result of this decision, the AMPE reallocated and refocused these resources towards select areas of India and other potential locations outside the U.S., based on the magnitude of cases of COVID-19.

  • Did Anything Boost Resgreen (RGGI) Stock Last Trading?

    In the last trading session, the stock price of leading mobile robot company Resgreen Group International Inc (OTCPink: RGGI) rose 23.08% to $0.0400. During the session, Resgreen stock traded between $0.0369 and $0.0520, while 9.28M shares were exchanged. Announcing its executive team expansion led to a rise in RGGI stock.

    How is RGGI expanding its team?

    As a leader in the field of Artificial Intelligence Robotics (AIRs), Autonomous Mobile Robots (AMRs), and Automatic Guided Vehicles (AGVs), Resgreen is at the forefront of this growing industry. With years of expertise in the material handling and robotics industries, RGGI engineers have invented numerous patents. RGGI consists of a variety of consulting services including backend operations, material handling assessments, work-flow analyses, and management system technology.

    Due to the company’s growth, Resgreen recently hired several new employees.

    • Carrie DiBattista has been hired as Director of Digital Marketing.
    • She will manage and direct the marketing and advertising efforts of the RGGI marketing team to build brand awareness and drive sales.
    • In early July of 2021, Isaac Hammons will begin his role as Manufacturing Manager within the newly opened facility in Shelby Township, Michigan.
    • RGGI has also been assembling a production team in order to streamline the process and meet growing demand.

    RGGI moved to larger facility:

    Earlier this month, ResGreen (RGGI) moved its manufacturing and production headquarters to Shelby Township, Michigan. As a response to the ever-increasing needs for the rapid development and fabrication of current and future products, RGGI has moved to a larger facility. RGGI, which will be working closely with a key supplier, Atlantic Precision Products, is able to add quality, efficiency, and speed to the growth, development, and manufacturing processes.

  • What Is Causing CLNE Stock To Rise Premarket?

    Shares of Clean Energy Fuels Corp. (CLNE) climbed to $12.12, an increase of 8.5% in premarket trading hours on Tuesday. As of the close of the last trading session, CLNE stock was trading at $11.17, up 3.43%.

    Prices ranged from $10.92 to $12.569 for CLNE stock. CLNE stock traded 61.39 million shares, more than its daily average of 11.23 million. CLNE stock rose after the unveiling of new visual identity designed to signify the company’s role in a future carbon-neutral world.

    The new visual identity for CLNE:

    Clean Energy provides the cleanest fuel for the transportation market in the United States. Through CLNE, a renewable natural gas (RNG) derived from organic waste decarbonizes transportation. With CLNE, thousands of vehicles can reduce greenhouse gas emissions, including airport shuttles, city buses, waste, and heavy-duty trucks. Across the US and Canada, CLNE operates more than 500 fueling stations.

    Yesterday, Clean Energy presented a new company logo, the cornerstone of an entirely new brand identity that mirrors the company’s commitment to expand its renewable fuel solutions.

    • As more companies seek solutions to climate change, the demand for low- and negative-carbon renewable fuel is rising.
    • CLNE, as the industry leader in RNG, is now at the forefront of helping customers meet their sustainability goals.
    • CLNE’s rebranding plans include investments in the development of RNG from dairies, alongside TotalEnergies and BP.
    • CLNE is on pace to sell RNG at all of its stations by 2025, meeting one of its own sustainability goals.
    • RNG currently makes up 70 percent of the fuel sold at CLNE’s stations.

    CLNE’s strategy:

    Clean Energy (CLNE) has pivoted its operations to focus on developing fuels that can reduce fleets’ carbon footprint by up to 500%. A new CLNE website, featuring updated information about the company’s focus on providing end-to-end solutions to meet the demands of RNG, was launched as part of the rebranding effort.

  • Is This Why The WRFX Stock Rose Last Trading?

    Astra Veda Corporation (OTC: WRFX) gained 15.00% to $0.0023 at yesterday’s close. Volumes for Astra stock were 91.08M versus its weekly average of 70.20M. WRFX stock increased when there was no current news, so there may be some grounds to believe that recent developments will provide more information about the WRFX.

    What has been happening recently at WRFX?

    Astra is a Wyoming-based company specializing in software applications, information security products, and technical innovation. The WRFX is a publicly-traded, multinational technology innovator, accelerator, and investment vehicle. By launching disruptive technology companies, WRFX delivers market success and extraordinary returns for its investors, employees, and business partners.

    Last month, Astra CEO Mick Davis announced a significant investment in a joint venture to manufacture Bullet Barrier Products.

    • Ballistic Barrier Products Inc. (BBP) will be in charge of developing, manufacturing and selling ballistic-resistant window and door coverings in order to satisfy the incredible demand in the market.
    • WRFX has identified a facility which is located within the heart of the textile industry in the south.
    • The facility benefits from close regional support in terms of materials, equipment, and skilled labor.
    • Within the next few months, BBP will be selling to residential and commercial customers as well as schools and government entities, both domestically and abroad.
    • Astra, Egres Enterprises, and Rift Management Inc. (RMI) are partners in the venture.
    • Astra focuses on co-founding technology companies and incubating them to success.

    WRFX’s role and strategy:

    Astra (WRFX) has invested in Bullet Barrier, its long-term strategy of developing products and services for the cyber security and life safety industries. Examples of this mindset include WRFX’s team in Finland, which has developed quantum computing resistant encryption as well as its Sayphr platform. As part of the new partnership, Astra will primarily be responsible for investing, controlling finances, and overseeing corporate governance.

  • How Did CynergisTek (CTEK) Stock Perform In Extended Trading?

    During Monday’s aftermarket session, CynergisTek Inc. (CTEK) shares fell -6.06% to $2.17. Following a gain in the regular session, CTEK stock has come to consolidate. CynergisTek stock added 13.79% to finish regular trading session at $2.31.

    CTEK recorded a trading volume of 1.07 million shares, which is high compared with the average daily trading volume of 0.22 million shares for the last 50 days. In the past three months, CTEK stock has declined -1.70 percent and gained 59.31 percent this year.

    CTEK recently experienced what?

    Cybersecurity company CynergisTek specializes in serving the needs of the healthcare industry. Providing security, privacy, and compliance solutions is a core competency of CTEK. In addition to serving hundreds of healthcare organizations as a partner, CynergisTek contributes to relevant industry associations to support and educate the industry. For the second year in a row, CTEK was named the top cybersecurity consultant for healthcare by Black Book in 2020.

    CynergisTek’s Redspin division recently achieved certification as a Candidate CMMC Third-Party Assessor Organization (C3PAO) under the Cybersecurity Maturity Model Certification Program (CMMC).

    • A Defense Industrial Base Cybersecurity Assessment Center (DIBCAC) of the Defense Contract Management Agency (DCMA) deemed that Redspin’s security practices and processes meet the requirements of CMMC Level 3.
    • In response, the CMMC Accreditation Body has certified CTEK’s Redspin as an Authorized C3PAO capable of conducting CMMC assessments.
    • CTEK’s division now has the authority to conduct assessments based on CMMC Levels 1-3 contractually with Organizations Seeking Certification (OSCs).
    • The Defense Industrial Base (DIB) contracts must be secured or renewed by CMMC contractors regardless of security negotiations.

    How CEO envision this going forward?

    Caleb Barlow, president and CEO of CynergisTek said that a number of resources at the company are on hand, and the last step was formal authorization that CynergisTek (CTEK) has now received. The CTEK executives, consultants, and provisional assessors are eager to assist DIB suppliers with assessing, constructing, and validating their cyber resilience.

  • Why Was The SIOX Stock Up 18% After Hours?

    On Monday, Sio Gene Therapies Inc. (SIOX) gained 18.25% to $2.98 in after-market trading. During the last trading session, shares of Sio Gene stock rose by 1.20% to close at $2.52. During the normal session, SIOX stock saw price of its shares ranging between $2.50 and $2.64.

    Recent developments:

    Sio Gene Therapies develops genetic medicines to help patients live longer, healthier lives. Among SIOX’s clinical-stage candidates are its potential curing AAV-based gene therapies for childhood diseases, including GM1 gangliosidosis and Tay-Sachs/Sandhoff, which are rare and uniformly fatal because of single gene defects. Also, SIOX is bringing gene therapy to treatments for Parkinson’s, which affects millions of people worldwide.

    Last week, Sio Gene reported its financial results for its fiscal year ended March 31, 2021.

    Financial Highlights:

    • As compared to the fiscal year ended March 31, 2020, research and development expenses of SIOX were $24.9 million in fiscal year 2021, a decrease of $22.2 million.
    • General and administrative expenses decreased by $4.8 million in comparison to the fiscal year ended March 31, 2020, and were $17.3 million in fiscal year 2021.
    • As of March 31, 2021, SIOX’s net loss was $32.4 million, which equates to $0.62 per share, compared to a loss of $72.6 million, or $2.93 per share, from March 31, 2020.
    • Net cash used by SIOX in operating activities for the fiscal year ended March 31, 2021 was $46.6 million.
    • The sale of long-term investment in Arvelle contributed $11.6 million to SIOX’s net cash provided by investing activities.

    SIOX’s strength:

    Sio Gene (SIOX) had cash and cash equivalents of $119.0 million as of March 31, 2021. There are no short- or long-term debts on the company’s balance sheet. SIOX estimated that it will be able to sustain operations up until the end of Q4 2022, beyond the anticipated dates for its AXO-AAV-GM1 gene therapy program to treat GM1 gangliosidosis.

  • Why SPAR Group Inc. (SGRP) stock lost its positive momentum in Monday’s after-market?

    Why SPAR Group Inc. (SGRP) stock lost its positive momentum in Monday’s after-market?

    SPAR Group Inc. (SGRP) shares lost 3.29% in after-market on Monday, June 14, 2021, and closed the day at $1.47 per share. Earlier, SGRP’s stock gained 2.01% in Monday’s session. SGRP shares have risen 78.84% over the last 12 months, and they have moved up 1.33% in the past week. Over the past three months, the stock has lost 10.32%, while over the past six months, it has added 47.57%.

    Let’s discuss its news and developments.

    Recent financial results

    On May 13, 2021, SPAR Group, Inc released its financial results for its first quarter ended March 31, 2021.

    Q1 2021 financial highlights

    • SPAR Group reported consolidated net revenue of $61.1 million in Q1 2021 compared to $61.3 million in Q1 2020.
    • Gross Profit was $12.3 million and gross margin was 20.1% in Q1 2021 compared to $11.8 million gross profit and 19.2% gross margin in Q1 2019.
    • Selling, General, and Administrative expenses were $9.01 million in Q1 2021 compared to $9.7 million in Q1 2020.
    • Operating Income was $2.7 million in Q1 2021 compared to $1.5 million in the prior year’s first quarter.
    • Net Income attributable to SPAR Group was $0.9 million in Q1 2021, compared to $0.3 million during the prior year’s first quarter.
    • Earnings per share were $0.04 in Q1 2021 compared to $0.01 in the prior year’s quarter.

    Increasing Credit Facility

    On May 04, 2021, SPAR Group, Inc increased and extended the terms of its current line of credit. The maximum amount of the line of credit increased by $2 million to $18 million and the length of the term was extended by 18 months to October 2023.

    Q4 and FY-2020 financial results announcement

    On March 31, 2021, SPAR Group, Inc released its financial results for its fourth quarter and fiscal year ended December 31, 2020. 

    Q4 2020 financial highlights

     

    • For Q4 2020 consolidated net revenue was $59.4 million compared to $61.1 million in the prior year’s fourth quarter.
    • Gross Profit was $11.5 million with a gross margin of 19.4% in Q4 2020 compared to $12.0 million gross profit and gross margin of 19.7% in the prior year’s fourth quarter.
    • Operating Income was $2.9 million in Q4 2020 compared to $1.2 million in the prior year’s fourth quarter.
    • Net Income was $2.0 million in Q4 2020 when compared to a net loss of $(0.6) million in the prior year’s quarter.
    • Earnings per share were $0.10, compared to a net loss of $0.03 in the prior year’s quarter. 

    FY2020 financial highlights

    • Consolidated net revenue was $230.5 million in FY 2020 compared to $252.9 million in the prior year.
    • Gross Profit was $45.2 million with a gross margin of 19.6%, in FY 2020 compared to $49.3 million gross profit and gross margin of 19.6% the prior year.
    • Operating Income was $9.7 million in FY 2020 compared to $10.2 million in FY 2019.
    • Net Income attributable to SPAR Group was $3.4 million in FY 2020 compared to $2.4 million in FY 2019.
    • Earnings per diluted share were$0.16 per share for FY 2020 compared to $0.11 per share in the prior year.

    Conclusion

    The SGRP lost in the after-market is a bit strange because there is no recent news as of this writing. We hope that SGRP stock will recover its loss on Tuesday.